A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

145

Participants

Timeline

Start Date

March 28, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

October 31, 2026

Conditions

Moderate to Severe Plaque Psoriasis

Interventions

DRUG

SHR-1139 Injection

SHR-1139 injection.

DRUG

SHR-1139 Injection Placebo

SHR-1139 injection placebo.

Trial Locations (1)

Shanghai Dermatology Hospital, Shanghai

All Listed Sponsors

lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY